EFFICACY AND SAFETY OF RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (SPIRIT 2)
OA: closed
CC0
⤵ 7 in-corpus citations
AI-generated summary
This Phase 3 trial evaluated the efficacy and safety of relugolix combination therapy for treating endometriosis-associated pain.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (7)
- Endometriosis: Molecular Pathophysiology and Recent Treatment Strategies-Comprehensive Literature Review 2024
- Novel pharmacological therapies for the treatment of endometriosis 2022
- Advances in targeting estrogen synthesis and receptors in patients with endometriosis 2022
- The latest advances in the pharmacological management of endometriosis 2022
- Medical treatments of endometriosis: a review 2022
- Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review 2021
- Thromboembolic safety profile of low-dose estradiol (valerate) in combined hormonal preparations: Implications for the development of new hormonal endometriosis and uterine fibroid therapies 2021
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0
· commercial use OK